Skip to main content

Fiscal Wizard · Single-issue tearsheet

JNJ / Jun 22, 2026 Run #7597

JNJ

Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Composite verdict

A 75.7 / 100
Bullish setup · Reversal 10 drivers · 4 gates blocking
  • MA Rejection
  • Vortex Signal
  • Pin Bar
Consider long call target Δ ~0.70 · ~35 DTE Bullish setup, Grade A → ITM call target

Industry rank 4th of 22 in Drug Manufacturers - General

rescore-sweep
Technical synthesisRegime: volatile range
Bull 100%Evidence: High · 19 signals0% Bear
Momentum Bullish 97Mean-reversion Neutral 50

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -77%
Asset value $33.87Earnings power value $72.96Price $228.39

Priced above its no-growth earnings power value ($72.96/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Mixed

51.4 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Margin of Safety 0
OCF to Net Income 83
Cash Conversion Cycle 0
Payout Ratio 82
Inventory Turnover 0

Technicals Bullish

99.9 / 100

Bullish setup leads (MA Rejection, Vortex Signal, Pin Bar); bears gated by guards. · 43 signals shown.

Strongest
Weakest
Vortex Signal 87
Coppock Curve 85
MA Rejection 83

Risk Gates

4 blocking 4 caution

4 guards active, 22 signals gated.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for JNJ.